36results about How to "Improve expression strength" patented technology

According to the novel human sensory neuron induction culture system provided by the invention, the combination of the small-molecule inhibitor LY2157299 and the growth factor is added into the serum-free basal culture medium, so that compared with a serum-containing induction method, the efficiency of converting pluripotent stem cells into sensory neurons is greatly improved, and the induction efficiency of the pluripotent stem cells is improved. In addition, the expression of various ion channel proteins is obviously improved, so that various induced pluripotent stem cells with different sources are successfully induced into sensory neurons.

The invention discloses an AhFAD2-2A gene promoter (P< AhFAD2-2A >) and an application of the AhFAD2-2A gene promoter, and belongs to the technical field of biology. A nucleotide sequence of the promoter is shown as SEQ ID NO.1. The AhFAD2-2A gene promoter is cloned from peanuts, and is used for building a recombinant expression vector; then, the recombinant expression vector is transformed into arabidopsis thaliana by an agrobacterium-mediated transformation method; a downstream recombinant gene is started to be expressed in seeds, roots and anthers, and is not expressed in other tissues; and the promoter belongs to a tissue specificity promoter, so that the promoter can be applied to transgenic engineering; a target gene expression product is accumulated in a certain organ or tissue; the expression amount in the tissue is increased; a good effect is achieved; meanwhile, the self energy waste of plants is avoided; and important application values are realized in the genetic engineering breeding and transgenic research process.

The present disclosure relates to polynucleotides having promoter activity and applications thereof in the production of amino acids. Specifically, the present disclosure relates to a polynucleotide having promoter activity, a transcription expression cassette containing the polynucleotide, a recombinant expression vector, a recombinant host cell, a method for enhancing expression of a target gene, a method for preparing a protein, and a method for producing an amino acid. The polynucleotide with the promoter activity is a mutant of the polynucleotide with the sequence as shown in SEQ ID NO: 9, compared with the polynucleotide with the sequence as shown in SEQ ID NO: 9, the promoter activity of the mutant is remarkably enhanced, stable and efficient expression of a target gene can be promoted, and then downstream products can be stably and efficiently produced.

The present invention relates to an improved PB transposon system and application thereof. Specifically, the present invention relates to a nucleic acid construct. The nucleic acid construct sequentially contains a promoter for controlling the expression of PiggyBac transposase, a PiggyBac transposase coding sequence, a terminal repeat at the 5'-end of the PiggyBac transposon, an optional polyA tailing signal sequence 1, a polyclonal insertion site, a polyA tailing signal sequence 2 and a terminal repeat at the 3'-end of the PiggyBac transposon. A recombinant vector constructed by using the nucleic acid construct provided by the invention has obviously improved integration efficiency.

The invention provides a recombinant staphylococcal enterotoxin I oral preparation, the recombinant staphylococcal enterotoxin I has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.

The invention relates to a strain of Xenorhabdus nematophila producing Xenocoumacin1 (Xcn1) in high yield. On the basis of a homologous recombination technology, genes related to anabolism of Xcn1 in a wild type strain of Xenorhabdus nematophila CB6 are subjected to engineering transformation to finally obtain an improved strain not producing Xcn2 but producing Xcn1 in high yield, named as CB6-T2. Studies show that an enzyme gene xcnM for mediating degradation and transformation of Xcn1 in the CB6-T2 strain is deleted and mutated, and a first gene xcnA promoter of an Xcn1 synthetic gene cluster is replaced with a promoter Promoter-g3509 that is derived from Xenorhabdus nematophila and has higher expression intensity. Tests show that the yield of Xcn1 obtained by fermenting the strain CB6-T2 in an LB culture medium is at least 782 mg/L or above, much higher than the fermentation yield of a wild strain of Xenorhabdus nematophila CB6. The strain can effectively reduce production cost in industrial development of Xcn1.

The invention provides a recombinant staphylococcal enterotoxin M oral preparation, the recombinant staphylococcal enterotoxin M has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.

The invention provides a recombinant staphylococcus aureus enterotoxin G oral preparation which has an amino acid sequence of SEQ ID NO.1 and also comprises excipients in medicine or carriers allowed by the preparation. By the experiment on the Caco-2 monolayer cell trans-membrane transport, the preparation of the invention proves that the proteins can enter the general blood circulation from intestinal epithelial cells in the form of complete molecules and keep promoting the splenic lymphocyte proliferation and preventing the superantigen activity for the growth of tumor cells, and can be applied to the preparation of drugs for curing the malignant tumor and other serious complications.

The invention provides a polynucleotide mutant with promoter activity. The polynucleotide mutant has higher promoter activity than a wild type promoter in an environment with increased salt concentration and osmotic pressure. Polynucleotide is operably connected with a target gene, so that the expression intensity of the target gene in a high-salt and high-osmotic-pressure stress environment can be remarkably improved, downstream products can be stably and efficiently produced, and the problems that expensive inducers such as IPTG are added currently, and toxicity is caused to strains are effectively solved.

The invention discloses a chimeric antigen receptor (CAR) targeting CD32b, an immune effector cell modified by the CAR, a preparation method of the immune effector cell and application of the immune effector cell in inhibition of chronic lymphocytic leukemia for the first time. The invention provides a novel treatment scheme for refractory chronic lymphocytic leukemia.

The invention relates to a PiggyBac transposon system and application thereof, and particularly provides a nucleic acid construct which comprises the following elements: a transposon 3 '-terminal repetitive sequence, a first polyA sequence, an insulator sequence with a transcription termination function, a transposon 5'-terminal repetitive sequence, a transposase coding sequence and a promoter for controlling the expression of the transposase. The invention further provides a host cell or a pharmaceutical composition containing the nucleic acid construct and application of the host cell or the pharmaceutical composition.

The invention provides a recombinant staphylococcal enterotoxin K oral preparation, the recombinant staphylococcal enterotoxin K has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.

The invention relates to application of a transcriptional regulation factor expressed by eukaryotic genes, in particular to application of a transcriptional regulation factor Hot1p of a constitutive promoter Pgap. The invention discloses application of Hot1p as a positive regulatory factor in improvement of protein expression in host cells. The amino acid sequence of the Hot1p is coded by an Hot1 gene with the nucleotide sequence of SEQ ID NO: 1; according to the application, an Hot1 gene is inserted behind a promoter Pgap, so that the expression of protein in host cells is improved. The application disclosed by the invention can enhance transcription of a constitutive promoter Pgap promoter of the pichia pastoris, so that a subsequent exogenous gene is efficiently expressed in the pichia pastoris, and the situation that the difference of expression quantities of different genes is too large due to a dilution effect generated by using the same promoter during multi-copy or multi-gene expression can be avoided.

The invention relates to an application of a transcriptional regulatory factor expressed by eukaryotic genes, in particular to an application of a transcriptional regulatory factor Msn2p of a constitutive promoter Pgap. The invention discloses application of Msn2p as a negative regulatory factor in improving protein expression in host cells. The amino acid sequence of the Msn2p is coded by an Msn2 gene with the nucleotide sequence of SEQ ID NO: 1; according to the application, expression of protein in host cells is improved by knocking out the Msn2 gene. According to the application disclosed by the invention, transcriptional regulation and control of the constitutive promoter Pgap in a pichia pastoris expression system can be enhanced by reducing a repression effect, so that the expression efficiency and the yield of target protein are improved.

The invention provides recombinant nitrile hydratase and application thereof in preparation of nicotinamide by coupling ion exchange resin, which comprises the following steps: by taking a concentrated solution of supernate obtained by ultrasonically crushing wet thalli obtained by fermentation culture of recombinant nitrile hydratase gene engineering bacteria as a catalyst and 3-cyanopyridine as a substrate, adding the ion exchange resin, and reacting at the temperature of between 20 and 30 DEG C to obtain the nicotinamide. The preparation method comprises the following steps: forming a reaction system by taking a phosphoric acid buffer solution with the pH value of 6-9 as a reaction medium, carrying out hydration reaction under the conditions of 20-30 DEG C and 100-1000rpm, and after the reaction is completed, separating and purifying the reaction liquid to obtain the product nicotinamide. The recombinant nitrile hydratase coupled ion exchange resin has the advantages of mild conditions, high efficiency, high chemical selectivity, regioselectivity and the like, the biological catalysis process has the characteristics of no toxicity, no pollution, low energy consumption and the like, the method is an environment-friendly synthesis method, 95% or more of nicotinic acid impurities are adsorbed, and the method is suitable for industrial production. The nicotinamide product with the purity of 99.99% or above is obtained.

The invention relates to application of a transcriptional regulatory factor expressed by eukaryotic genes, in particular to application of a transcriptional regulatory factor Ash1p of a constitutive promoter Pgap. The invention discloses application of Ash1p as a negative regulatory factor in improvement of protein expression in host cells. The amino acid sequence of the Ash1p is coded by an Ash1 gene with the nucleotide sequence of SEQ ID NO: 1; according to the application, expression of protein in host cells is improved by knocking out the Ash1 gene. According to the application disclosed by the invention, transcriptional regulation and control of the constitutive promoter Pgap in a pichia pastoris expression system can be enhanced by reducing a repression effect, so that the expression efficiency and the yield of target protein are improved.

The invention provides a recombinant staphylococcal enterotoxin O oral preparation, the recombinant staphylococcal enterotoxin O has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.